SCHEMBL21371583

SCHEMBL21371583

CC(C)(C)c1cc(N)c(SCCNC(=N)N)c(NC(=O)c2cc(OCCNC(=N)N)cc(C(N)=O)c2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
CASP3 P42574 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
F10 P00742 2/20 0.33
MAPT P10636 4/20 0.32
SRC P12931 1/20 0.32
SYK P43405 1/20 0.32
GSK3A P49840 1/20 0.32
MAPK14 Q16539 1/20 0.32
SIRT2 Q8IXJ6 1/20 0.31
SIRT1 Q96EB6 1/20 0.31
SIRT3 Q9NTG7 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RECQL P46063 1/20 0.31
LMNA P02545 2/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL86141 0.97 NPC1 (0.36) NPC1RAB9APOLBCASP3SENP7
SCHEMBL10198578 0.96 NPC1 (0.35) NPC1RAB9APOLBCASP3SENP7
SCHEMBL11927704 0.92 PLAU (0.33) NPC1RAB9APOLBCASP3SENP7
SCHEMBL11932631 0.86 CA12 (0.40) NPC1RAB9APOLBCASP3SENP7
SCHEMBL10288224 0.86 NPC1 (0.39) NPC1RAB9APOLBF10MAPT
SCHEMBL85496 0.84 PTGS1 (0.37) NPC1RAB9ACASP3SENP7MAPT
SCHEMBL85773 0.83 KMT2A (0.33) NPC1RAB9APOLBCASP3SENP7
SCHEMBL10198582 0.82 PLK4 (0.37) NPC1RAB9ACASP3SENP7MAPT
SCHEMBL13309979 0.82 KMT2A (0.32) RAB9AMEN1KMT2A
SCHEMBL11927711 0.81 PLAU (0.37) NPC1RAB9APOLBCASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10603294-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2020-03-31 US disclosed
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis POLYMEDIX, INC. 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10603294-B2 Compounds for use in treatment of mucositis MUC1, FUT6, MMP8 NPC1 571/4885RAB9A 2835/4885POLB 1562/4885
US-20190282521-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 NPC1 571/4885RAB9A 2835/4885POLB 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.